By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Merz Pharma GmbH & Co. KGaA 

Eckenheimer Landstra├če 100-104

Frankfurt am Main    D-60318  Germany
Phone: 49-69-15-03-1 Fax: 49-0-69-15-03-200


SEARCH JOBS


Industry
Pharmaceutical


Collaborations

Forest Laboratories, Inc.  Licensing agreement for the development and marketing in the U.S. of memantine for the treatment of Alzheimer's Disease and neuropathic pain. Licensing agreement for neramexane, a patented novel NMDA receptor antagonist that is being investigated for a broad range of possible indications related central nervous system disorders.





Company News
Forest Laboratories, Inc. (FRX) Files Lawsuit Against Several Companies For Infringement Of NAMENDA XR ® Patents 2/3/2014 7:17:47 AM
Forest Laboratories, Inc. (FRX), Merz Pharma GmbH & Co. KGaA Settle Patent Dispute Over Namenda 7/23/2010 7:16:14 AM
Neurobiological Technologies, Inc. (NTII) Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine 2/3/2009 8:26:16 AM
Forest Laboratories, Inc. (FRX) and Merz Pharma GmbH & Co. KGaA File Additional Lawsuit Against Several Companies for Patent Infringement 1/25/2008 11:20:45 AM
Forest Laboratories, Inc. (FRX) and Merz GmbH & Co. KGaA File Lawsuits Against Several Companies for Patent Infringement 1/11/2008 7:54:30 AM
Bernhard Scheuble Appointed As CEO Of The MERZ Group 9/27/2006 1:51:01 PM
Neurobiological Technologies, Inc. (NTII) Receives $1.1 Million Royalty Payment Related To Memantine10/19/2005 5:10:41 PM
Forest Laboratories, Inc. (FRX) Announces That Neramexane Did Not Demonstrate Statistical Significance In Recently Completed Phase III Trial In Patients With Moderate To Severe Alzheimer's Disease10/19/2005 5:10:29 PM
Merz GmbH & Co. KGaA Release: Memantine Captures US Market 10/19/2005 5:10:11 PM
Neurobiological Technologies, Inc. (NTII) Receives $2.25 Million Payment Related To Alzheimer's Drug10/19/2005 5:09:55 PM
//-->